Posted on 10/12/2009 in Pharmaceutical Company Product News Sanofi-aventis has signed a contract with Alopexx, which will see the two firms collaborate to license a first-in-class human monoclonal antibody for the treatment and prevention of serious infections, such as S aureus, S epidermidis, E. coli and Y pestis.
The antibody in question is currently in the development stages and will cater to an unmet medical need.
As part of the agreement, Alopexx will bring the product into phase I clinical trials during 2010, while Sanofi-aventis will be offered the option to take up the exclusive worldwide license for the drug.
Marc Cluzel, executive vice-president of research and development at Sanofi-aventis, said that the product "could become, if developed to its full potential, a key driver of our company's anti-infective portfolio with a strong position in the prevention and treatment of resistant infections".
Last month, Sanofi-aventis revealed that its drug Multaq (dronedarone 400mg Tablets) - which is indicated for use in patients with current non-permanent atrial fibrillation - has been approved by the European commission.Other news stories from 10/12/2009
Read more in the Zenopa News Archive
How this news is generated
|
